The real-life nature of our study was designed to directly inform that need, investigating pre-to-post biologic change in asthma outcomes along a gradient for three biomarkers used routinely in clinical practice (i.e., BEC, FeNO, and IgE), for three biologic classes (i.e., anti-IgE, anti-IL5/5R and anti-IL4Rα), and across 3 asthma outcomes (i.e., exacerbation rate, asthma control, and lung function). Here, IGHE is linked to asthma.